Novavax plans FDA filing after NanoFlu trumps Sanofi flu vaccine

Novavax has unveiled new Phase III data showing that its recombinant quadrivalent seasonal influenza vaccine candidate, NanoFlu, met all primary endpoints in adults aged 65 and older against Sanofi’s Fluzone Quadrivalent. As a results of the successful data, the company has announced plans to submit a filing to the […]

Click here to view original web page at

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.